Condition
Renal
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (2)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05568966Not ApplicableRecruiting
Collection of Blood Samples for New Diagnostic Devices 2
NCT00972205Not ApplicableCompleted
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
NCT01054261Phase 1CompletedPrimary
To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.
NCT00423254Phase 1Completed
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Showing all 4 trials